Bryan Somerville, Chief Operating Officer of BurnsAdler, remarked, "We arevery pleased to receive approval for Collatamp(TM) EG in Brazil and for theopportunity to bring this advanced technology into a new market.Collatamp(TM) EG is the only Gentamycin-impregnated Collagen Sponge in theworld, and allows medical providers to reduce patient costs and meanduration of hospital stay. Through our strategic partnership with Meizlerand direct promotional efforts, we look forward to positive results inBrazil."

Avi Meizler, President of Meizler, remarked, "It is a great pleasure toshare with you the approval and very soon launching of Collatamp(TM) inBrazil. We are truly confident that this very valuable product -- withinthe Brazilian market -- will definitely contribute in the improvement ofthe medical practices and, of course, better quality of life for thepatients. We are also looking forward to sharing with our partners,BurnsAdler Pharmaceuticals, the success of Collatamp(TM) in the very nearfuture."

About Collatamp(TM) EG

Collatamp(TM) EG is based on Innocoll Inc.'s proprietary collagenCollaRx® (collagen sponge matrix) drug delivery technology. It isapproved in over 50 countries worldwide and is marketed under a variety ofother trade names in Europe, the Middle East, Africa and Asia. BurnsAdlerlicensed the product for sale in various Latin American countries fromInnocoll Pharmaceuticals in August 2006. In 2007, EUSA Pharma Inc. acquiredall worldwide rights from Innocoll, with the exception of the U.S., and allagreements with BurnsAdler were maintained.

About Meizler Biopharma, S.A.

Meizler is a Brazilian medical and hospital-focused company that has beenin existence for eighteen years. The company has held several internationalpartnerships with a variety of companies in Europe, the United States andAsia. Meizler's portfolio currently includes products in the followingcategories: anesthetic, antipsychotic, antibiotics, biotechnology-vaccines,cardiovascular, haemoderivaties and human reproduction hormones.www.meizler.com.br

About BurnsAdler Pharmaceuticals, Inc.

BurnsAdler is a specialty pharmaceutical company that in-licenses andpromotes products in South America, Mexico, Canada, Puerto Rico and theCaribbean. BurnsAdler's portfolio currently includes products targeted forthe gastroenterology, cardiovascular, orthopedic, oncology, and criticalcare markets.

For additional information about this news release contact Natalie Legra at+1.704.552.8410 Ext. 232. For additional information about BurnsAdler,please refer to the company's website at www.burnsadler.com.